A simple blood test could be used to identify patients whose melanoma – the most serious form of skin cancer – has started to spread to other parts of the body, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
“This work could lead to quicker diagnosis and potentially new treatments, giving patients and doctors an even better chance of beating the disease” – Dr Harpal Kumar, NCRI chair
Researchers from Dundee examined DNA shed from tumour cells into the bloodstream, looking at a single gene called TFP12.
The gene usually helps to stop healthy skin cells growing out of control, which could potentially lead to cancer. But the researchers found that in melanoma patients it acquires chemical ‘tags’ – known as DNA methylation – that switch this gene off.
They also found that levels of this ‘switch off’ correlated with whether or not the cancer had spread around the body. Early stage tumours had relatively low levels of DNA methylation, while advanced cancers had much higher levels, suggesting the gene was more tightly shut down.
The results suggest that measuring the levels of methylated TFP12 in DNA in the blood could be a useful test to inform doctors whether a patient’s melanoma has started to spread and needs additional treatment.
Dr Tim Crook, study author and a consultant medical oncologist based at the University of Dundee, said: “Once melanoma starts to spread it becomes far more difficult to treat. But actually detecting whether or not it has started to spread is also challenging.
“By using a blood test, we have the basis of a simple and accurate way of discovering how advanced the disease is, as well as an early warning sign of whether it has started to spread. This would give doctors and patients important information much sooner than is possible at the moment. There’s increasing evidence that the latest treatments are more effective in these early stages and, if we can identify patients whose cancer has only just started to spread, this would significantly improve the chances of beating the disease.”
The study was supported by Barts and the London Charity, The Brain Tumour Research Charity (BTRC), The Leng Foundation, The Medical Research Council, and Tayside Tissue Bank.
The same team has identified another potential biomarker – NT5E. This gene appears to become methylated and switched off as melanoma first develops. But if NT5E becomes unmethylated again, the gene is reactivated and helps the disease to spread more aggressively.
The researchers suggest that NT5E could be a possible target for developing new treatments to tackle melanoma, particularly for aggressive cancers that have spread to the brain, lungs and other organs.
Professor Charlotte Proby, Cancer Research UK dermatologist based at the University of Dundee, said: “Using blood tests to assess the landscape of our DNA is a simple way to learn more about what’s going on under the skin. The switching on and off of certain genes seems to affect when, where and why the melanoma spreads. Our goal is to develop a panel of similar biomarkers that will help us to accurately detect those patients needing extra treatment to fight their melanoma.
Dr Harpal Kumar, chief executive of Cancer Research UK and chair of the NCRI, said: “Thanks to research, more than eight in 10 people now survive melanoma for at least 10 years. But there’s still more work to be done to improve things further, particularly for those patients whose cancer has spread to other organs.
“This work could lead to quicker diagnosis and potentially new treatments, giving patients and doctors an even better chance of beating the disease.”
For media enquiries please contact the press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059
View the Conference abstract here